Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Osiris Therapeutics Inc. (NASDAQ:OSIR) gained $0.25 to $5.55 last week after Health Canada granted Prochymal conditional approval to treat acute graft-versus-host disease (GvHD) in children. Prochymal is an IV formulation of mesenchymal stem cells. Osiris said the decision is the world's first regulatory approval of a manufactured stem cell product and the first therapy approved for GvHD. A launch in Canada is expected this year.
Active Biotech AB (SSE:ACTI) was up SEK1.50 to SEK40.80 on Friday after oral tasquinimod led to median overall survival of 34.2 months vs. 30.2 months for placebo in a Phase II trial in asymptomatic, metastatic castration-resistant prostate cancer